SCHEMBL10226264

SCHEMBL10226264

CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H]1CC[C@@]2(C)C(CCC3C2CC[C@@]2(C)C3CC[C@@H]2C(C)CCC(=O)N(CC(=O)O)CC(=O)O)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHA2 P29317 4/20 0.53
▸ GPBAR1 Q8TDU6 3/20 0.53
▸ VDR P11473 2/20 0.53
▸ CASP7 P55210 3/20 0.51
▸ TP53 P04637 2/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ BLM P54132 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ USP2 O75604 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ HIF1A Q16665 2/20 0.51
▸ MDM4 O15151 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ HSPD1 P10809 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ PTPN2 P17706 1/20 0.51
▸ PTPN1 P18031 1/20 0.51
▸ BRCA1 P38398 1/20 0.51
▸ HSPE1 P61604 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16923217 1.00 EPHA2 (0.53) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL16923215 0.92 GPBAR1 (0.49) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL10226298 0.92 GPBAR1 (0.49) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL10226261 0.92 GPBAR1 (0.61) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL10226251 0.92 GPBAR1 (0.61) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL18629123 0.89 USP2 (0.54) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL14978143 0.89 USP2 (0.54) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL18629132 0.89 USP2 (0.54) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL24193196 0.88 USP2 (0.53) EPHA2GPBAR1VDRCASP7TP53
SCHEMBL21101187 0.88 USP2 (0.53) EPHA2GPBAR1VDRCASP7TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962580-B2 Chemical modifications of monomers and oligonucleotides with cycloaddition ALNYLAM PHARMACEUTICALS, INC. (US) 2015-02-24 — — US disclosed
US-8962580-B2 Chemical modifications of monomers and oligonucleotides with cycloaddition ALNYLAM PHARMACEUTICALS, INC. (US) 2015-02-24 — — US disclosed
US-20120035115-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-09 — — US disclosed
US-20120035115-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035115-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION DNMT1, LCK, MCTS1 EPHA2 538/4885GPBAR1 2010/4885VDR 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback